FRIDAY, April 25, 2025 (HealthDay News) -- On Tuesday, the U.S. Department of Health and Human Services announced that the ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

Moderna (NasdaqGS:MRNA) experienced a 10% share price increase, coinciding with broader market gains but slightly below the Nasdaq Composite's 5% rise. Despite the market being uplifted by strong ...

the U.S. Department of Health and Human Services announced that the government will invest $176 million in Moderna to expedite the creation of a pandemic influenza vaccine, according to a report ...

The FDA has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a post-approval ...

Bernstein lowered the firm’s price target on Moderna (MRNA) to $28 from $39 given recent political headwinds for the stock, while keeping a ...

FRIDAY, April 25, 2025 (HealthDay News) -- On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in Moderna to expedite the creation ...